Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $10.00, for a total value of $150,000.00. Following the completion of the sale, the vice president now owns 35,517 shares of the company’s stock, valued at approximately $355,170. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Curt A. Herberts III also recently made the following trade(s):
- On Thursday, June 1st, Curt A. Herberts III sold 2,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $6.80, for a total value of $13,600.00.
- On Friday, May 12th, Curt A. Herberts III sold 2,639 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $8.02, for a total value of $21,164.78.
Sangamo Therapeutics, Inc. (NASDAQ SGMO) remained flat at $8.40 during mid-day trading on Thursday. The company’s stock had a trading volume of 141,424 shares. The firm has a 50 day moving average of $8.85 and a 200-day moving average of $5.93. The company’s market capitalization is $604.29 million. Sangamo Therapeutics, Inc. has a 1-year low of $2.65 and a 1-year high of $10.50.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.03. Sangamo Therapeutics had a negative net margin of 380.44% and a negative return on equity of 50.76%. The company had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $4.14 million. During the same quarter last year, the company posted ($0.23) EPS. The firm’s revenue was down 12.8% compared to the same quarter last year. On average, analysts expect that Sangamo Therapeutics, Inc. will post ($0.93) earnings per share for the current year.
SGMO has been the subject of a number of analyst reports. Jefferies Group LLC restated a “buy” rating and set a $17.00 target price on shares of Sangamo Therapeutics in a report on Thursday, June 22nd. BidaskClub lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Zacks Investment Research lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. ValuEngine upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Finally, Wedbush restated a “neutral” rating and set a $4.00 target price (down previously from $6.00) on shares of Sangamo Therapeutics in a report on Tuesday, May 16th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $8.50.
Large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. purchased a new stake in Sangamo Therapeutics during the fourth quarter valued at about $179,000. A.R.T. Advisors LLC purchased a new stake in Sangamo Therapeutics during the fourth quarter valued at about $161,000. Tudor Investment Corp Et Al purchased a new stake in Sangamo Therapeutics during the fourth quarter valued at about $201,000. Metropolitan Life Insurance Co. NY boosted its stake in Sangamo Therapeutics by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 780 shares during the period. Finally, Teachers Advisors LLC boosted its stake in Sangamo Therapeutics by 4.9% in the fourth quarter. Teachers Advisors LLC now owns 164,728 shares of the biopharmaceutical company’s stock valued at $502,000 after buying an additional 7,693 shares during the period. 58.25% of the stock is owned by institutional investors and hedge funds.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
